Clinical Systems for RBC Fragility
Blaze’s technology holds future promise in multiple clinical areas. A feasible routine test for RBC mechanical fragility could help inform decisions of hospital blood bankers and transfusing clinicians for enhanced patient safety and improved blood product utilization. Published data indicates that storage time alone may not be a good predictor of transfusion efficacy and thus of clinical outcomes. RBC mechanical fragility testing may aid in assessing quality for stored blood product, based on the ability of cell membranes to resist hemolysis. On the diagnostic side, mechanical fragility of RBC can be compromised as a result of various diseases and pathologies – diabetes, sepsis, sickle cell disease, and various other anemias. Many of these could provide a target for development of new diagnostic approaches and patient treatment monitoring or evaluation. Blaze’s technology could potentially enable broader use of mechanical fragility analysis in patient treatment.
Product lines for such clinical applications will be designed to perform testing quickly and with minimal effort from medical personnel, making them suitable for use in a hospital or clinical laboratory. Types and formats of results provided by such systems would be product-specific, targeted to particular applications. Prior to and during development of any medical versions of Blaze’s technology, data from appropriate clinical research users will be collected regarding each potential area of application.